Programmed Cell Death Ligand (PD-L1) testing changes to pathology MBS item 72814

This page provides information regarding the amendment to pathology MBS item 72814 for Programmed Cell Death Ligand (PD-L1) testing

Page last updated: 30 September 2022

From 1 October 2022, MBS item 72814 for PD-L1 immunohistochemistry testing of tumour material from a patient diagnosed with non-small cell lung cancer, will be amended to also include testing of tumour material from a patient diagnosed with recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx.

The Medical Services Advisory Committee (MSAC) supported amending MBS item 72814 to include PD-L1 immunohistochemistry testing for patients with recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx to determine a patient's suitability for treatment with Pharmaceutical Benefits Scheme (PBS) listed pembrolizumab.

Further information can be found in the Factsheet below:

PDF Version Factsheet for amendment to pathology MBS item 72814 (PDF 165 KB)
Word Version Factsheet for amendment to pathology MBS item 72814 (Word 119 KB)

In this section